Last updated on March 2019

Riociguat in Children With Pulmonary Arterial Hypertension (PAH)


Brief description of study

This study is designed to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of riociguat at age-, sex- and body-weight-adjusted doses of 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID in children from 6 to less than 18 years with pulmonary arterial hypertension (PAH) group 1. The study consists of two phases: titration phase up to 8 weeks and a maintenance phase up to 16 weeks.

Clinical Study Identifier: NCT02562235

Contact Investigators or Research Sites near you

Start Over

Bayer Clinical Trials Contact

Toho University Omori Medical Center
Ota-ku, Japan
0.7miles
  Connect »

Bayer Clinical Trials Contact

Keio University Hospital
Shinjuku-ku, Japan
8.31miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.